XAMSVVY
Market cap53mUSD
Dec 20, Last price
1.97EUR
1D
0.51%
1Q
-6.19%
Jan 2017
-88.85%
IPO
-91.52%
Name
Vivoryon Therapeutics NV
Chart & Performance
Profile
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | (3,620) | 10,764 | ||||||||
Cost of revenue | 20,387 | 38,028 | 23,570 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (24,007) | (38,028) | (12,806) | |||||||
NOPBT Margin | 663.18% | |||||||||
Operating Taxes | (234) | (199) | 432 | |||||||
Tax Rate | ||||||||||
NOPAT | (23,773) | (37,829) | (13,238) | |||||||
Net income | (28,342) 0.66% | (28,156) 122.49% | (12,655) -23.35% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 26,346 | 35,247 | (737) | |||||||
BB yield | -12.82% | -15.51% | 0.19% | |||||||
Debt | ||||||||||
Debt current | 38 | 94 | 92 | |||||||
Long-term debt | 38 | 76 | 264 | |||||||
Deferred revenue | (1) | |||||||||
Other long-term liabilities | 1,365 | 1,335 | 2,348 | |||||||
Net debt | (28,507) | (26,399) | (17,778) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (21,541) | (21,794) | (11,257) | |||||||
CAPEX | (14) | (13) | (28) | |||||||
Cash from investing activities | (10,514) | (13) | (28) | |||||||
Cash from financing activities | 24,157 | 33,381 | (827) | |||||||
FCF | (22,705) | (38,079) | (12,490) | |||||||
Balance | ||||||||||
Cash | 28,583 | 26,555 | 14,661 | |||||||
Long term investments | 14 | 3,473 | ||||||||
Excess cash | 28,764 | 26,569 | 17,596 | |||||||
Stockholders' equity | (122,732) | (96,532) | (72,822) | |||||||
Invested Capital | 150,417 | 124,448 | 91,900 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 25,242 | 22,020 | 20,000 | |||||||
Price | 8.14 -21.12% | 10.32 -45.68% | 19.00 110.88% | |||||||
Market cap | 205,471 -9.58% | 227,242 -40.20% | 380,000 111.14% | |||||||
EV | 176,964 | 200,843 | 362,222 | |||||||
EBITDA | (23,840) | (37,867) | (12,641) | |||||||
EV/EBITDA | ||||||||||
Interest | 56 | 24 | 24 | |||||||
Interest/NOPBT |